Vaccine compositions and methods
The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.
1. A pharmaceutical composition comprising an adjuvant and a chaperone rich cell lysate (CRCL), wherein the adjuvant comprises living immune cells where at least a portion are activated T-cells in infusion media with cross-linked CD3 and CD28 surface molecules;
wherein the source of the CRCL is a malignant tumor and the CRCL comprises multiple chaperone complexes enriched by free solution-isoelectric focusing; and
wherein the administration of the composition to a host generates a Th-1 response.
2. The composition of claim 1 wherein the T-cells are memory T-cells of the Th-1 phenotype.
3. The composition of claim 1 wherein the cross-linking of the CD3 and CD28 surface molecules on the T-cells is by anti-CD3 and anti-CD28 monoclonal antibodies.
4. The composition of claim 1 wherein the activated T-cells express CD40L.
5. The composition of claim 1 wherein the T-cells are allogeneic to the host.
6. The composition of claim 1 further comprising one or more tumor associated antigens.